{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:48:41Z","timestamp":1782395321377,"version":"3.54.5"},"posted":{"date-parts":[[2024,8,21]]},"group-title":"Bioinformatics","reference-count":66,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with non-metastatic triple-negative (TNBC) or HER2-positive (HER2+) breast cancer do not have tools to predict treatment response or prioritize options prior to starting therapy. Pathologic complete response (pCR) is a proxy that requires neoadjuvant treatment. BC-SELECT leverages genetic interactions (e.g. synthetic lethality (SL)\/rescue (SR)) to predict treatment response via pCR from breast cancer gene expression data. BC-SELECT involves (1) \u201cgene-pair identification\u201d that identifies clinically relevant partner genes from large-scale datasets for a given targeted therapy or immunotherapy target, and (2) \u201ctraining \/ parameter tuning\u201d using clinical trials to predict treatment response. We evaluated BC-SELECT\u2019s ability to predict pCR for trastuzumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy, with tuning supported by three trials (n=86) and validation on nine unseen trials (n=722).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>BC-SELECT significantly predicted pCR in 6\/9 trials, including all PARP inhibitors (ROC-AUCs 0.6-0.8; Odds Ratio (OR): 1.9-3.5) and immunotherapy (ROC-AUCs 0.7-0.8; OR: 3.2-7.1). BC-SELECT significantly distinguished between pCR and residual disease in 8\/9 trials.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No current standard-of-care, pre-treatment approaches predict benefit in non-metastatic TNBC and HER2+ breast cancer. BC-SELECT leverages genetic interactions to predict treatment response from gene expression data. Our findings support development of BC-SELECT towards prioritizing PARP inhibitors and immunotherapy in non-metastatic breast cancer.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.08.15.608073","type":"posted-content","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T05:25:15Z","timestamp":1724563515000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing transcriptome-based synthetic lethality predictions to improve targeted therapy \/ immunotherapy treatment prioritization in non-metastatic breast cancer: BC-SELECT"],"prefix":"10.64898","author":[{"given":"Yewon","family":"Kim","sequence":"first","affiliation":[{"name":"Cancer and Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nagy","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pollard","sequence":"additional","affiliation":[{"name":"Cancer and Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma Sheila","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Cancer and Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"},{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026062506050552000_2024.08.15.608073v4.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.178"},{"key":"2026062506050552000_2024.08.15.608073v4.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873"},{"key":"2026062506050552000_2024.08.15.608073v4.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253"},{"key":"2026062506050552000_2024.08.15.608073v4.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710"},{"key":"2026062506050552000_2024.08.15.608073v4.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"2026062506050552000_2024.08.15.608073v4.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-177"},{"key":"2026062506050552000_2024.08.15.608073v4.7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.671"},{"key":"2026062506050552000_2024.08.15.608073v4.8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3044"},{"key":"2026062506050552000_2024.08.15.608073v4.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-4020"},{"key":"2026062506050552000_2024.08.15.608073v4.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"2026062506050552000_2024.08.15.608073v4.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"2026062506050552000_2024.08.15.608073v4.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103220"},{"key":"2026062506050552000_2024.08.15.608073v4.13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4591"},{"key":"2026062506050552000_2024.08.15.608073v4.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"2026062506050552000_2024.08.15.608073v4.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101207"},{"key":"2026062506050552000_2024.08.15.608073v4.16","unstructured":"Maintenance Pembrolizumab\/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC. OncLive. December 6, 2023. Accessed September 1, 2024. https:\/\/www.onclive.com\/view\/maintenance-pembrolizumab-olaparib-misses-survival-end-points-in-locally-advanced-or-metastatic-tnbc"},{"key":"2026062506050552000_2024.08.15.608073v4.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26502-6"},{"key":"2026062506050552000_2024.08.15.608073v4.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3478"},{"key":"2026062506050552000_2024.08.15.608073v4.19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6288"},{"key":"2026062506050552000_2024.08.15.608073v4.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.005"},{"key":"2026062506050552000_2024.08.15.608073v4.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01743-z"},{"key":"2026062506050552000_2024.08.15.608073v4.22","unstructured":"Stewart Mark . Digital and Computational Pathology Tool Harmonization PATH Project Session 1 Presentation. Digital PATH Project Working Group, Friends of Cancer Research. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Digital-and-Computational-Pathology-Tool-Harmonization-PATH-Project-Session-1-Presentation.pdf"},{"key":"2026062506050552000_2024.08.15.608073v4.23","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer v.4.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"2026062506050552000_2024.08.15.608073v4.24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-GS03-09"},{"key":"2026062506050552000_2024.08.15.608073v4.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0055-6"},{"key":"2026062506050552000_2024.08.15.608073v4.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2017.47"},{"key":"2026062506050552000_2024.08.15.608073v4.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"2026062506050552000_2024.08.15.608073v4.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098"},{"key":"2026062506050552000_2024.08.15.608073v4.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1508573112"},{"key":"2026062506050552000_2024.08.15.608073v4.30","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188323"},{"key":"2026062506050552000_2024.08.15.608073v4.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.030"},{"key":"2026062506050552000_2024.08.15.608073v4.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.11.001"},{"key":"2026062506050552000_2024.08.15.608073v4.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30111-6"},{"key":"2026062506050552000_2024.08.15.608073v4.34","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-1943"},{"key":"2026062506050552000_2024.08.15.608073v4.35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866"},{"key":"2026062506050552000_2024.08.15.608073v4.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101928"},{"key":"2026062506050552000_2024.08.15.608073v4.37","doi-asserted-by":"publisher","DOI":"10.3390\/cells12202457"},{"key":"2026062506050552000_2024.08.15.608073v4.38","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1084"},{"key":"2026062506050552000_2024.08.15.608073v4.39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0552"},{"key":"2026062506050552000_2024.08.15.608073v4.40","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx390.033"},{"key":"2026062506050552000_2024.08.15.608073v4.41","unstructured":"LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics - Adashek - 2023 - Cancer Medicine - Wiley Online Library. Accessed February 19, 2025. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/cam4.6000"},{"key":"2026062506050552000_2024.08.15.608073v4.42","unstructured":"Clinical blockade of PD1 and LAG3 \u2014 potential mechanisms of action | Nature Reviews Immunology. Accessed February 19, 2025. https:\/\/www.nature.com\/articles\/nri3790"},{"key":"2026062506050552000_2024.08.15.608073v4.43","unstructured":"STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer | npj Breast Cancer. Accessed February 19, 2025. https:\/\/www.nature.com\/articles\/s41523-022-00471-5"},{"key":"2026062506050552000_2024.08.15.608073v4.44","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-6394"},{"key":"2026062506050552000_2024.08.15.608073v4.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01103-4"},{"key":"2026062506050552000_2024.08.15.608073v4.46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30860"},{"key":"2026062506050552000_2024.08.15.608073v4.47","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022113190"},{"key":"2026062506050552000_2024.08.15.608073v4.48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e12598"},{"key":"2026062506050552000_2024.08.15.608073v4.49","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01748-8"},{"key":"2026062506050552000_2024.08.15.608073v4.50","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(22)00188-1"},{"key":"2026062506050552000_2024.08.15.608073v4.51","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e31"},{"key":"2026062506050552000_2024.08.15.608073v4.52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450"},{"key":"2026062506050552000_2024.08.15.608073v4.53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056"},{"key":"2026062506050552000_2024.08.15.608073v4.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2023.12.009"},{"key":"2026062506050552000_2024.08.15.608073v4.55","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad976"},{"key":"2026062506050552000_2024.08.15.608073v4.56","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0138"},{"key":"2026062506050552000_2024.08.15.608073v4.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00427-9"},{"key":"2026062506050552000_2024.08.15.608073v4.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00219-7"},{"key":"2026062506050552000_2024.08.15.608073v4.59","unstructured":"nCounter Breast Cancer 360. NanoString. 2024. Accessed July 8, 2024. https:\/\/nanostring.com\/products\/ncounter-assays-panels\/oncology\/breast-cancer-360\/"},{"key":"2026062506050552000_2024.08.15.608073v4.60","unstructured":"PanCancer Immune Profiling. NanoString. 2024. Accessed July 8, 2024. https:\/\/nanostring.com\/products\/ncounter-assays-panels\/oncology\/pancancer-immune-profiling\/"},{"key":"2026062506050552000_2024.08.15.608073v4.61","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00435"},{"key":"2026062506050552000_2024.08.15.608073v4.62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0239"},{"key":"2026062506050552000_2024.08.15.608073v4.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201105109"},{"key":"2026062506050552000_2024.08.15.608073v4.64","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-5-51"},{"key":"2026062506050552000_2024.08.15.608073v4.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04278-5"},{"key":"2026062506050552000_2024.08.15.608073v4.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.15.608073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:05:32Z","timestamp":1782392732000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.08.15.608073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1101\/2024.08.15.608073","relation":{},"subject":[],"published":{"date-parts":[[2024,8,21]]},"subtype":"preprint"}}